Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Characteristics of MIT-001 After Subcutaneous and Intravenous Administration in Healthy Subjects

Next Previous
Trial Profile

Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Characteristics of MIT-001 After Subcutaneous and Intravenous Administration in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MIT 001 (Primary) ; MIT 001 (Primary)
  • Indications Asthma; COVID 2019 infections; Graft-versus-host disease; Idiopathic pulmonary fibrosis; Stomatitis
  • Focus Pharmacokinetics
  • Sponsors MitoImmune Therapeutics

Most Recent Events

  • 22 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 20 Mar 2023 Planned End Date changed from 1 Jul 2023 to 10 Jun 2023.
  • 20 Mar 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top